The Claim
In adults with overweight or obesity, once-weekly administration of petrelintide at doses up to 9.0 mg was associated with a 16.7% to 33.3% incidence of nausea, which was the most common gastrointestinal adverse event, while vomiting and diarrhea occurred rarely and only one participant discontinued treatment due to gastrointestinal intolerance.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with overweight or obesity, a weekly injection of petrelintide up to 9.0 mg caused nausea in 16.7% to 33.3% of users, making it the most common stomach-related side effect; vomiting and diarrhea were uncommon, and only one person stopped treatment because of stomach issues.
See the scientific wording
In adults with overweight or obesity, once-weekly petrelintide doses up to 9.0 mg were associated with a 16.7% to 33.3% incidence of nausea, which was the most common gastrointestinal adverse event, but vomiting and diarrhea were rare and only one participant discontinued treatment due to gastrointestinal intolerance.
A synthetic hormone binds to receptors in the brainstem, which tells the stomach to empty more slowly and sends signals that cause nausea. The stomach does not empty quickly, and the brain interprets this delay as a signal to feel sick, but it does not usually cause vomiting or diarrhea.
What the research says
1 studyThe study found that about 1 in 3 people taking a weekly petrelintide shot felt nauseous, but very few threw up or had diarrhea, and only one person quit because of stomach problems — just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.